These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 22364579

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Are the short-acting insulin analogs superfluous?].
    Arand M.
    MMW Fortschr Med; 2006 Mar 16; 148(11):17. PubMed ID: 16612957
    [No Abstract] [Full Text] [Related]

  • 3. Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.
    Dunn CJ, Plosker GL.
    Pharmacoeconomics; 2002 Mar 16; 20(14):989-1025. PubMed ID: 12403639
    [Abstract] [Full Text] [Related]

  • 4. Long-acting insulin analogs versus human insulins.
    Garg SK, Naik RG.
    Diabetes Technol Ther; 2008 Oct 16; 10(5):331-2. PubMed ID: 18715208
    [No Abstract] [Full Text] [Related]

  • 5. Hypoglycaemia: costs, insulins and prevention.
    Holt RI.
    Diabet Med; 2016 Apr 16; 33(4):419-20. PubMed ID: 26995756
    [No Abstract] [Full Text] [Related]

  • 6. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
    Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G.
    Diabetes Obes Metab; 2009 Nov 16; 11(11):1068-79. PubMed ID: 19732121
    [Abstract] [Full Text] [Related]

  • 7. [Economics under scrutiny - experts discuss long acting insulin analogs].
    Pflege Z; 2011 Jan 16; 64(1):58. PubMed ID: 21305792
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of insulin analogs.
    Brixner DI, McAdam-Marx C.
    Am J Manag Care; 2008 Nov 16; 14(11):766-75. PubMed ID: 18999911
    [Abstract] [Full Text] [Related]

  • 10. [My quality of life has increased with Lantus].
    Euler H.
    Lakartidningen; 2004 Sep 23; 101(39):3015; discussion 3016. PubMed ID: 15493645
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes.
    Crasto W, Jarvis J, Khunti K, Davies MJ.
    Postgrad Med J; 2009 May 23; 85(1003):257-67. PubMed ID: 19520878
    [Abstract] [Full Text] [Related]

  • 13. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P.
    Diabetes Obes Metab; 2008 Jul 23; 10 Suppl 2():66-75. PubMed ID: 18577158
    [Abstract] [Full Text] [Related]

  • 14. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark].
    Palmer AJ, Lammert M, Hermansen K.
    Ugeskr Laeger; 2008 Apr 07; 170(15):1250-4. PubMed ID: 18433583
    [Abstract] [Full Text] [Related]

  • 15. [Short acting insulin analogues for type 2 diabetes. Unnecessary additional expenditure or valuable added benefit? Interview by Böhm Sanja].
    Hess R, Kerner W.
    Dtsch Med Wochenschr; 2006 Oct 27; Suppl 1():36-7. PubMed ID: 17595817
    [No Abstract] [Full Text] [Related]

  • 16. An update on the long-acting insulin analogue glargine.
    Thisted H, Johnsen SP, Rungby J.
    Basic Clin Pharmacol Toxicol; 2006 Jul 27; 99(1):1-11. PubMed ID: 16867163
    [Abstract] [Full Text] [Related]

  • 17. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
    Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M.
    Diabet Med; 2012 Mar 27; 29(3):303-12. PubMed ID: 21951030
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective.
    Pollock RF, Valentine WJ, Pilgaard T, Nishimura H.
    J Med Econ; 2011 Mar 27; 14(1):36-46. PubMed ID: 21192769
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.